References
- FDA. Prescribing information for naltrexone: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf
- http://www.lowdosenaltrexone.org/
- ALS Therapy Development Institute forums: http://www.als-tdf.org/forum/Default.aspx?g=posts&t=47657
- Modesto-Lowe V, van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol. 2002;10: 213–27.
- Panerai AE, Radulovic J, Monastra G, Manfredi B, Locatelli L, Sacerdote P. Beta-endorphin concentrations in brain areas and peritoneal macrophages in rats susceptible and resistant to experimental allergic encephalomyelitis: a possible relationship between tumor necrosis factor alpha and opioids in the disease. J Neuroimmunol. 1994;51: 169–76.
- McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001;62:111–23.
- Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102:820–8. Epub 2007, Jan 11.
- Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology. 2010;68:145–50.
- Niebroj-Dobosz I, Dziewulska D, Janik P. Auto-antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Folia Neuropathol. 2006;44:191–6.
- Holmøy T. T-cells in amyotrophic lateral sclerosis. Eur J Neurol. 2008;15:360–6. Epub 2008, Feb 11.
- Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378–83.
- Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, . Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009;10:393–404.
- Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol. 1996;243:117–20.
- Lyeth BG, Jiang JY, Gong QZ, Hamm RJ, Young HF. Effects of mu opioid agonist and antagonist on neurological outcome following traumatic brain injury in the rat. Neuropeptides. 1995;29:11–9.
- Baskin DS, Hosobuchi Y, Grevel JC. Treatment of experimental stroke with opiate antagonists: effects on neurological function, infarct size, and survival. J Neurosurg. 1986;64:99–103.
- Su DS, Wang ZH, Zheng YJ, Zhao YH, Wang XR. Dose-dependent neuroprotection of delta opioid peptide (D-Ala2, D-Leu5) enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats. Neurosci Lett. 2007;423:113–7. Epub 2007, Aug 6.
- Silani V, Perini M, Fayoumi ZM, Scarlato G. Naloxone of no benefit in amyotrophic lateral sclerosis. Ann Neurol. 1983;13:222.